Y-mAbs Therapeutics, Inc.’s Post

Metrika, an IQVIA business, provides essential information to both new and established pharmaceutical and biotechnology companies in the oncology market, enhancing their strategies and optimizing their interactions with oncologists and #cancer treatment providers. Available now, the latest addition to the 2023 OncoMETRIKS reports, the 3rd edition of the Canadian Patient Support Program (PSP) Evaluation Report, serves as a valuable tool for benchmarking your #PSP against the best in the marketplace, or if you are planning to launch one, it will help you as a best practice blueprint. Watch for the 2023 OncoMETRIKS Oncology Corporate Leadership, Oncology Sales Force Performance, and Oncology Medical Education Evaluation reports coming later this year --> https://bit.ly/3EjCRlG @Arushi_Sharma @Nikhil_Nath #patientsupport #cdnpharma #oncologyPSP

My favorite oncology news of the week: 💰 Lilly ($LLY) adds one more deal to the growing list of radiopharmaceutical deals. Lilly will collaborate with Aktis oncology for target discovery with $60M upfront payment and up to $1.1B in milestone payments. https://lnkd.in/efuVrfdY 💡 Cool approach of loading L.plantarum with SN-38 (irinotecan pro-drug) to target heparan sulfate-rich nasopharyngeal carcinoma cells, with decent activity in mice. https://lnkd.in/eedjuHAJ ⬆ Merus' petosentamab is one of my most anticipated presentations for #ASCO24. Not only does the drug seem very active in HNSCC, it also has a novel target (LGR5). n=10; one complete response, five partial responses, and three instances of stable disease. https://lnkd.in/e_F4YhkA

TOS) has just completed enrollment for its Phase 2 EVANGELINE clinical trial, evaluating (Z)-endoxifen for ER+ / HER2- breast cancer. Plus, insider buying signals strong confidence in the company's future! 💰 Want to get in on this trade? Check out our recommended buy levels, target prices, and stop loss details. With a potential upside of 27% to 53%, this $1 stock offers 2x to 3x more potential upside than downside! #Investment #StockMarket #AtossaTherapeutics #Biopharma #TradingTips #StrongBuy 

Global Precision Oncology Market Trends and Growth Opportunities Report 2023: Public-private Partnerships Will Propel Access and Adoption of Precision Oncology Enhancing Integrated Solutions: DUBLIN, Dec. 8, 2023 /PRNewswire/ -- The "Global Precision Oncology Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study highlights current technological trends and emphasizes the interdisciplinary efforts underway to ensure that a...

Accelerated approval is an important tool that faciliates earlier patient access to promising therapies by allowing approval based on an early endpoint likely to predict clinical benefit. Confirming the clinical benefit through timely postmarketing confirmatory studies is essential to ensure patients have access to therapies that are safe and effective. Check out the Friends of Cancer Research drug development dashboard to gain data driven insights around the status of Accelerated Approvals and their post-marketing requirements, and endpoints used as the basis for Accelerated and full approvals. Accelerate Approval Dashboard: https://lnkd.in/enknuAgD #oncology #Friends #Patients #Research

Following the Association of Value-Based Cancer Care (AVBCC) Summit last week, we identified four critical takeaways from the conference that are most impactful for our manufacturer clients. What do they mean for the future of oncology across the pharmaceutical industry? Read our blog to learn more. #pharma #biotech #oncology #IRA #VBA #healthequity #marketaccess Valuate Health Consultancy Entrée Health

Ratio’s CDO Jacob Hesterman, Ph.D., recently co-authored a paper in the Journal of Clinical Oncology titled, “How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.”      The article addresses several issues regarding #radiopharmaceutical therapy (RPT) trials in oncology, including the designation of absorbed dose (AD) constraints by the FDA and the dearth of reporting on patient tissue ADs and toxicities.     At Ratio, our commitment to radiopharmaceutical therapies extends beyond the development of our own technology platforms. We’re proud to contribute to improving industry-wide practices for radiopharmaceutical clinical trials. Faster, more efficient trials mean these potentially life-changing treatment reach patients in need sooner.     Read the full article: https://lnkd.in/enH8Rdk6     #radiopharmaceuticals #radiotherapeutics #oncology 

"Connect with our team of oncology experts at #ASH23 to discover how EVERSANA ONCOLOGY Commercialization™ and analytics are revolutionizing the oncology drug pipeline with agility and data-driven solutions. #oncology #drugpipeline #ASH23 #commercialization #analytics #dataanalytics #ai

Longitude portfolio company Alpha-9 Oncology and NorthStar Medical Radioisotopes, LLC recently announced a long-term strategic supply agreement for NorthStar to provide Alpha-9 with its non-carrier added (n.c.a.) Ac-225 for use in its targeted radiopharmaceutical programs for treatment of solid and liquid tumors. "The Alpha-9 team is well positioned to progress multiple targets into the clinic," said Alpha-9 Oncology CEO David Hirsch, MD, Ph.D. "Robust supply of high-quality Ac-225 will help us advance a new generation of highly effective radiopharmaceuticals with improved tumor uptake and limited off-target exposure. We look forward to working with NorthStar and bringing our molecules to patients." Learn more about the new agreement: https://lnkd.in/enZfyRZP #radiopharmaceuticals #biotech #biotechnology

Cancer research is increasing with the sole goal of providing tailored therapies to the patients; every journey is different. “A priority for everyone… as it relates to improving equitable treatment access and making sure patients’ quality of life is considered alongside drug efficacy”. Two FDA initiatives: - Project Optimus: Evaluate early dose optimisation considering full impact of toxicity - Project FrontRunner: Develop and seek approval for advanced cancers in earlier clinical setting From drug-centered to patient-centred approaches to improve health outcomes and expand treatment access to all. See below for full article (p.60-64).